IFP Advisors’s UroGen Pharma URGN Stock Holding History

IFP Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.14K	Hold	31	–	–	﹤0.01%	4456
2026 Q1	$557	Hold	31	–	–	﹤0.01%	4394
2025 Q4	$726	Sell	31 -3	-9%	-$65	﹤0.01%	4174
2025 Q3	$678	Sell	34 -128	-79%	-$2.3K	﹤0.01%	4087
2025 Q2	$2.22K	Buy	+162	New	+$1.55K	﹤0.01%	3852
2025 Q1	–	Sell	-4	Closed	-$43	–	4640
2024 Q4	$43	Buy	+4	New	+$48	﹤0.01%	4302

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

IFP Advisors's URGN Position: Q2 2026 in Review

IFP Advisors held its UroGen Pharma (URGN) position steady in Q2 2026 at 31 shares worth $1.14K. The position accounts for ﹤0.01% of the portfolio, ranked #4456.

IFP Advisors first reported a position in URGN in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.22K in Q2 2025. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

IFP Advisors held 31 shares of UroGen Pharma worth $1.14K as of Q2 2026.
IFP Advisors left its UroGen Pharma share count unchanged in Q2 2026.
UroGen Pharma made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4456 holding.
IFP Advisors first reported a position in UroGen Pharma in Q4 2024 and has held it in 6 quarters since.
IFP Advisors's UroGen Pharma position peaked at $2.22K in Q2 2025.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.